Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May 10:8:163-9.
doi: 10.2147/CEOR.S98848. eCollection 2016.

Economic burden of refractory chronic spontaneous urticaria on Kuwait's health system

Mona Al-Ahmad  1 , Maryam S Alowayesh  2 , Norman V Carroll  3
Affiliations

Economic burden of refractory chronic spontaneous urticaria on Kuwait's health system

Mona Al-Ahmad et al. Clinicoecon Outcomes Res. .

Abstract

Background: Chronic spontaneous urticaria (CSU) is a common problem worldwide. We evaluated the direct medical costs of treating patients with refractory CSU and the budget effect of omalizumab use in these patients in Kuwait.

Methods: The prevalence of CSU was estimated using the Delphi method. Medical records of patients with refractory CSU in Kuwait were reviewed. Costs were calculated from a health system perspective. One-way sensitivity analyses were conducted on the price and utilization of each cost component.

Results: Before omalizumab use, the total direct costs of treating 1,293 patients with refractory CSU were estimated to be USD 3,650,733 per year. This estimation was principally generated by outpatient visits. After omalizumab use, the cost was sensitive to price variation and estimated to be USD 15,828,612 per year. All other direct costs were reduced.

Conclusion: The economic burden of refractory CSU in Kuwait is high. Omalizumab use is costly, but its administration reduces all other direct costs.

Keywords: Kuwait; Middle East; chronic urticaria; cost; economic; omalizumab.

PubMed Disclaimer

References

    1. Zuberbier T, Asero R, Bindslev-Jensen C, et al. Dermatology Section of the European Academy of Allergology and Clinical Immunology. Global Allergy and Asthma European Network. European Dermatology Forum. World Allergy Organization EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy. 2009;64(10):1417–1426. - PubMed
    1. Grattan CE, Sabroe RA, Greaves MW. Chronic urticaria. J Am Acad Dermatol. 2002;46(5):645–657. quiz 657–660. - PubMed
    1. Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993;328(22):1599–1604. - PubMed
    1. Altrichter S, Peter HJ, Pisarevskaja D, Metz M, Martus P, Maurer M. IgE mediated autoallergy against thyroid peroxidase – a novel pathomechanism of chronic spontaneous urticaria? PLoS One. 2011;6(4):e14794. - PMC - PubMed
    1. Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011;128(1):202–209.e205. - PubMed

LinkOut - more resources